To hear about similar clinical trials, please enter your email below
Trial Title:
A Study for Treatment of Superficial Bladder Cancer Using OGX-427
NCT ID:
NCT00959868
Condition:
Bladder Cancer
Conditions: Official terms:
Urinary Bladder Neoplasms
Conditions: Keywords:
Bladder cancer
Superficial bladder cancer (Ta or T1)
Muscle invasive bladder cancer (T2)
Transurethral resection
Radical cystectomy
OGX-427
Antisense oligonucleotide
Heat shock protein 27
superficial bladder tumour (Ta or T1) or CIS prior to a transurethral resection
Muscle invasive (T2) bladder cancer prior to radical cystectomy
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Unknown status
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
OGX-427
Description:
OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution
packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium
sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an
aluminum, red, flip-off over seal. The drug product is aseptically compounded and
sterilized via sterile filtration prior to aseptic filling.
Summary:
This is a single centre, open label, phase I dose escalation trial using a modified
accelerated titration design. Patients with superficial bladder tumour (Ta or T1) or CIS
and candidates for transurethral resection or muscle invasive disease (>T2) and
candidates for radical cystectomy will be enrolled.
OGX-427 will be given neoadjuvantly over 8 days, followed by a transurethral resection
(for superficial disease) or radical cystectomy (for muscle invasive disease).
Baseline Hsp27 levels will be determined from pre-treatment cytological samples from
bladder washings and tumour biopsies performed prior to therapy.
Post-treatment PK and PD data will be determined from TUR (for Ta, T1 tumours) or radical
cystectomy (for T2 tumours) specimens. A recommended phase II dose will be determined
from the toxicity, tissue pK, and percentage of Hsp27 knockdown. Effects of treatment on
Hsp27 client protein levels and apoptotic index will also be evaluated.
Evaluation during protocol treatment will take place to assess toxicity. Assessments will
occur on various visits as per Evaluation Schedule. Adverse event evaluation based on NCI
CTCAEv3.0. For quality of life assessment during treatment, the EORTC QLC-BLS24 will be
used before first treatment (day 1) and prior to surgery (TURBT or radical cystectomy).
The Day 1 QOL assessment will serve as baseline.
After removal from protocol treatment, all subjects will be followed for toxicity related
to study drug for 30 days.
After the study, subjects will be followed according to standard of care. Follow-up for
tumour recurrence or superficial tumours will be assessed every three months by
cystoscopic examination for two years, then every six months for the next two years, and
then yearly thereafter.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Patient age must be > 18
2. Histologic evidence of bladder cancer (superficial or muscle invasive) or
CIS as evidenced by:
- Patients presenting with superficial tumours and unknown pathological stage
will have in-clinic bladder washings (performed cystoscopically) and biopsy
(cup biopsy).
- Patients with recurrent superficial disease (Ta or T1) and tissue that is
available for baseline studies (i.e. tissue from previous transurethral
resection stored in paraffin blocks) will be eligible for trial without
requiring cytology or biopsy.
- Patients with previously diagnosed T1 tumours and requiring re-resection
of bladder tumour will be eligible if tissue from the original TURBT is
available for baseline studies.
- Patients presenting as muscle invasive (>T2) disease will be eligible if
they are candidates for radical cystectomy and if baseline tissue from
initial resections is available for baseline studies
3. No intravesical therapies within the previous 6 months
4. No evidence of metastatic disease as determined by physical exam, CT scan or chest-
x-ray, where indicated.
5. ECOG status must be 0, 1, or 2
6. Laboratory requirements (within 7 days of treatment):
- negative urine cultures
- Absolute neutrophils count> 1.5 x 109 cells/L, and platelets count> 100 x
109/L,
- Total bilirubin < 1.5 x upper normal limit (ULN), AST and/or ALT < 1.5 x ULN,
alkaline phosphatase < 1.5 x ULN, and serum creatinine < 1.5 x ULN.
- PTT and INR, within normal limits
7. Patient must be able to complete the quality of life questionnaires in either
English or French
8. Patients must provide written informed consent.
Exclusion Criteria:
1. Patients with "indeterminate" or "negative" results from biopsy or cytology will be
ineligible for the trial.
2. Patients taking warfarin or Coumadin anticoagulation therapy or who have a bleeding
disorder. NOTE: Patients who require anticoagulation therapy while on study will be
removed from study treatment.
3. Pregnant or lactating women
4. Patients not accessible for follow-up
5. Patients with an active urinary tract infection, upper tract urothelial tumors,
active infection including tuberculosis, concurrent febrile illness or impaired
immune response from any cause
6. Patients with contraindication to spinal or general anesthesia required for a
transurethral resection or radical cystectomy
7. Recent (<14 days) urethral trauma or inability to perform catheterization or
cystoscopy safely
8. Patients known to have a serious illness or medical condition that would impair
protocol treatment delivery.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
The Prostate Centre at Vancouver General Hospital
Address:
City:
Vancouver
Zip:
V5Z 1M9
Country:
Canada
Status:
Recruiting
Contact:
Last name:
Maureen Palmer, RN
Phone:
604-875-5675
Email:
Maureen.Palmer@vch.ca
Investigator:
Last name:
Alan I So, MD, FRCSC
Email:
Principal Investigator
Investigator:
Last name:
Peter C Black, MD, FRCSC
Email:
Sub-Investigator
Investigator:
Last name:
Edward C Jones, MD, FRCPC, LMCC
Email:
Sub-Investigator
Start date:
July 2009
Lead sponsor:
Agency:
Vancouver Coastal Health
Agency class:
Other
Collaborator:
Agency:
NCIC Clinical Trials Group
Agency class:
Other
Collaborator:
Agency:
Vancouver General Hospital Foundation
Agency class:
Other
Source:
Vancouver Coastal Health
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT00959868